Altimmune (NASDAQ:ALT) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Altimmune (NASDAQ:ALT) in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock.

A number of other equities research analysts have also recently weighed in on ALT. Wall Street Zen upgraded shares of Altimmune from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, June 27th. UBS Group reduced their price target on shares of Altimmune from $26.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday. JMP Securities decreased their price objective on shares of Altimmune from $25.00 to $15.00 and set a “market outperform” rating for the company in a report on Thursday, July 10th. Finally, B. Riley dropped their target price on Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.40.

Altimmune Trading Up 3.3%

Shares of NASDAQ ALT opened at $3.74 on Wednesday. The stock has a 50 day simple moving average of $4.83 and a 200-day simple moving average of $5.33. The company has a market cap of $303.35 million, a PE ratio of -3.17 and a beta of -0.01. Altimmune has a 12-month low of $2.90 and a 12-month high of $11.16.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. Altimmune had a negative return on equity of 65.97% and a negative net margin of 438,730.03%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Sell-side analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Altimmune

Large investors have recently made changes to their positions in the business. Ameriprise Financial Inc. raised its position in shares of Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock worth $37,888,000 after purchasing an additional 1,378,854 shares during the period. Geode Capital Management LLC boosted its position in shares of Altimmune by 13.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after purchasing an additional 228,995 shares during the period. Bellevue Group AG increased its stake in Altimmune by 9.5% in the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock worth $6,817,000 after purchasing an additional 81,786 shares in the last quarter. Northern Trust Corp raised its holdings in Altimmune by 5.7% during the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock worth $4,801,000 after buying an additional 35,918 shares during the period. Finally, Two Sigma Investments LP lifted its stake in Altimmune by 33.2% during the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock valued at $4,364,000 after buying an additional 151,001 shares in the last quarter. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.